Cargando…
Helicobacter Pylori-Induced Gastric Infections: From Pathogenesis to Novel Therapeutic Approaches Using Silver Nanoparticles
Helicobacter pylori is the first formally recognized bacterial carcinogen and the most important single digestive pathogen responsible for the induction of gastroduodenal diseases such as gastritis, peptic ulcer, and, finally, gastric neoplasia. The recently reported high rates of antimicrobial drug...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318142/ https://www.ncbi.nlm.nih.gov/pubmed/35890358 http://dx.doi.org/10.3390/pharmaceutics14071463 |
_version_ | 1784755219144376320 |
---|---|
author | Pop, Romelia Tăbăran, Alexandru-Flaviu Ungur, Andrei Paul Negoescu, Andrada Cătoi, Cornel |
author_facet | Pop, Romelia Tăbăran, Alexandru-Flaviu Ungur, Andrei Paul Negoescu, Andrada Cătoi, Cornel |
author_sort | Pop, Romelia |
collection | PubMed |
description | Helicobacter pylori is the first formally recognized bacterial carcinogen and the most important single digestive pathogen responsible for the induction of gastroduodenal diseases such as gastritis, peptic ulcer, and, finally, gastric neoplasia. The recently reported high rates of antimicrobial drug resistance hamper the current therapies of H. pylori, with therapeutic failure reaching up to 40% of patients. In this context, new treatment options and strategies are urgently needed, but the successful development of these new therapeutic tools is conditioned by the understanding of the high adaptability of H. pylori to the gastric acidic environment and the complex pathogenic mechanism. Due to several advantages, including good antibacterial efficiency, possible targeted delivery, and long tissular persistence, silver nanoparticles (AgNPs) offer the opportunity of exploring new strategies to improve the H. pylori therapy. A new paradigm in the therapy of H. pylori gastric infections using AgNPs has the potential to overcome the current medical limitations imposed by the H. pylori drug resistance, which is reported for most of the current organic antibiotics employed in the classical therapies. This manuscript provides an extensive overview of the pathology of H. pylori-induced gastritis, gastric cancer, and extradigestive diseases and highlights the possible benefits and limitations of employing AgNPs in the therapeutic strategies against H. pylori infections. |
format | Online Article Text |
id | pubmed-9318142 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93181422022-07-27 Helicobacter Pylori-Induced Gastric Infections: From Pathogenesis to Novel Therapeutic Approaches Using Silver Nanoparticles Pop, Romelia Tăbăran, Alexandru-Flaviu Ungur, Andrei Paul Negoescu, Andrada Cătoi, Cornel Pharmaceutics Review Helicobacter pylori is the first formally recognized bacterial carcinogen and the most important single digestive pathogen responsible for the induction of gastroduodenal diseases such as gastritis, peptic ulcer, and, finally, gastric neoplasia. The recently reported high rates of antimicrobial drug resistance hamper the current therapies of H. pylori, with therapeutic failure reaching up to 40% of patients. In this context, new treatment options and strategies are urgently needed, but the successful development of these new therapeutic tools is conditioned by the understanding of the high adaptability of H. pylori to the gastric acidic environment and the complex pathogenic mechanism. Due to several advantages, including good antibacterial efficiency, possible targeted delivery, and long tissular persistence, silver nanoparticles (AgNPs) offer the opportunity of exploring new strategies to improve the H. pylori therapy. A new paradigm in the therapy of H. pylori gastric infections using AgNPs has the potential to overcome the current medical limitations imposed by the H. pylori drug resistance, which is reported for most of the current organic antibiotics employed in the classical therapies. This manuscript provides an extensive overview of the pathology of H. pylori-induced gastritis, gastric cancer, and extradigestive diseases and highlights the possible benefits and limitations of employing AgNPs in the therapeutic strategies against H. pylori infections. MDPI 2022-07-14 /pmc/articles/PMC9318142/ /pubmed/35890358 http://dx.doi.org/10.3390/pharmaceutics14071463 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Pop, Romelia Tăbăran, Alexandru-Flaviu Ungur, Andrei Paul Negoescu, Andrada Cătoi, Cornel Helicobacter Pylori-Induced Gastric Infections: From Pathogenesis to Novel Therapeutic Approaches Using Silver Nanoparticles |
title | Helicobacter Pylori-Induced Gastric Infections: From Pathogenesis to Novel Therapeutic Approaches Using Silver Nanoparticles |
title_full | Helicobacter Pylori-Induced Gastric Infections: From Pathogenesis to Novel Therapeutic Approaches Using Silver Nanoparticles |
title_fullStr | Helicobacter Pylori-Induced Gastric Infections: From Pathogenesis to Novel Therapeutic Approaches Using Silver Nanoparticles |
title_full_unstemmed | Helicobacter Pylori-Induced Gastric Infections: From Pathogenesis to Novel Therapeutic Approaches Using Silver Nanoparticles |
title_short | Helicobacter Pylori-Induced Gastric Infections: From Pathogenesis to Novel Therapeutic Approaches Using Silver Nanoparticles |
title_sort | helicobacter pylori-induced gastric infections: from pathogenesis to novel therapeutic approaches using silver nanoparticles |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318142/ https://www.ncbi.nlm.nih.gov/pubmed/35890358 http://dx.doi.org/10.3390/pharmaceutics14071463 |
work_keys_str_mv | AT popromelia helicobacterpyloriinducedgastricinfectionsfrompathogenesistonoveltherapeuticapproachesusingsilvernanoparticles AT tabaranalexandruflaviu helicobacterpyloriinducedgastricinfectionsfrompathogenesistonoveltherapeuticapproachesusingsilvernanoparticles AT ungurandreipaul helicobacterpyloriinducedgastricinfectionsfrompathogenesistonoveltherapeuticapproachesusingsilvernanoparticles AT negoescuandrada helicobacterpyloriinducedgastricinfectionsfrompathogenesistonoveltherapeuticapproachesusingsilvernanoparticles AT catoicornel helicobacterpyloriinducedgastricinfectionsfrompathogenesistonoveltherapeuticapproachesusingsilvernanoparticles |